Safety and Tolerability of BDB-001 Injection in Healthy Subjects

Healthy Clinical Trial

Official title:

A Randomized, Double-blind,Placebo-controlled,Single-Ascending Dose Phase Ⅰ Study to Evaluate the Safety,Tolerability,and Pharmacokinetics of BDB-001 Injection in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05360927
• Other study ID #: STS-BDB001-01
• Status: Completed
• Phase: Phase 1
• Start date: September 25, 2019
• Est. completion date: December 25, 2020

Study information

• Verified date: April 2022
• Source: Staidson (Beijing) Biopharmaceuticals Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A clinical study to evaluate the safety,tolerability,PK and PD characteristics of BDB-001 Injection in healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: December 25, 2020
• Est. primary completion date: December 25, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Aged = 18 but = 65, male and female;

• Medical histories, physical examinations, laboratory examinations and study-related examinations and tests of the subjects,the Investigator judges that they are healthy;

• Body weight: 50- 80 kg, inclusive; Body mass index: 18.0 -26.0 kg/m2, inclusive;

• Vital signs: Blood pressure (90 mmHg= systolic =140 mmHg, 50 mmHg= diastolic =90 mmHg), heart rate (50= heart rate =100 beats/min), body temperature < 37°C;

• Subjects (including their partners) agree to take highly effective contraceptive measures during the study, and they have no birth plan or sperm donation plan within 6 months after the end of the study;

• Subjects are aware of the risks of the study, and voluntarily participate in the clinical study and sign an informed consent form (ICF).

Exclusion Criteria:

• History of cardiovascular, respiratory, kidney, liver, metabolism, endocrine, gastrointestinal, blood, nerve, skin and mental illness, cancer or other major disease that in the judgment of the Investigator might put the subject as risk on this study;

• Past history of tuberculosis, history of contact with active tuberculosis, TB-SPOT test results exceeding the upper limit of 2 times or more, and recent infectious diseases;

• During the screening and baseline period, the white blood cell count and C-reactive protein test results are abnormal and have clinical significance, hemoglobin: male <120g/L or female <110g/L;

• Electrocardiogram (ECG) abnormalities and have clinical significance;

• Subjects who have an autoimmune disease or an immune deficiency disease, or a family history of an autoimmune disease or an immune deficiency disease;

• Subjects with clinically obvious allergic diseases;

• Positive screening test results for human immunodeficiency virus (HIV-1/HIV-2) antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV-Ab), treponema pallidum antibody;

• Participate in any drug or vaccine clinical trial as a subject within 3 months before screening or prepare to be vaccinated during the study period to 2 months after the end of the study;

• Have received any monoclonal antibody or biological agent treatment within the previous 3 months;

• Have taken drugs that may affect immune function within 6 months before screening or have taken prescription/over-the-counter drugs within the previous 14 days;

• Subjects who have donated either more than approximately 500 mL of blood within 3 months prior to screening or any plasma within 4 weeks prior to screening; Subjects who donated blood (>400 ml) within 3 months prior to screening, or plasma exchange within 4 weeks prior to screening;

• Drink more than 5 cups of coffee, tea or cola per day (150ml and above per cup);

• Subjects who test positive for alcohol or drugs during the screening;

• Subjects who smoke or smoke test results are positive;

• Subjects with poor compliance;

• Pregnant or lactating women;

• The investigator believes that there are any subjects who are not suitable to participate in this trial.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• BDB-001 injection
Intravenous injection
• Placebo
Intravenous injection

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Staidson (Beijing) Biopharmaceuticals Co., Ltd	Beijing Defengrei Biotechnology Co.,Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities And Clinically Significant Physical Examination Abnormalities		Up to 50 days
Primary	Maximum plasma concentration (Cmax)		Up to 1200 hours postdose
Primary	Area under the plasma concentration-time curve from time 0 to infinity (AUC0inf)		Up to 1200 hours postdose
Primary	Area under the plasma concentration-time curve from time 0 to 1200hr(AUC00-1200hr)		Up to 1200 hours postdose
Primary	Time of maximum concentration (Tmax)		Up to 1200 hours postdose
Primary	Elimination half-life (t1/2)		Up to 1200 hours postdose
Primary	Clearance (CL)		Up to 1200 hours postdose
Primary	Apparent volume of distribution (Vz)		Up to 1200 hours postdose
Primary	Mean residence time (MRT)		Up to 1200 hours postdose
Secondary	Number of participants developing anti-BDB-001 antibodies		Up to 50 days